Shares of Valeant Pharmaceuticals International (VRX) Sees Large Outflow of Money

Valeant Pharmaceuticals International (VRX) : Net money flow in Valeant Pharmaceuticals International (VRX) was negative ($2.85 million) and the inflow of money on uptick was $107.56 million, whereas, the outflow of money on downticks amounted to $110.41 million on Thursday. The traders used every opportunity of price strength in the stock to sell their positions, hence, the total uptick to downtick ratio was 0.97. The block trades show that the large investors, were aggressive sellers in the stock. The total value of block trades on upticks was only $13.58 million. On the other hand, the total value of block trades done on downticks was $6.71 million. The ratio of uptick to downtick block trades was 2.02. The money flow in block trades was negative ($6.87). Valeant Pharmaceuticals International (VRX) gained $0.16 cent during the day and reached $23.22, a gain of 0.7% over the previous day.


Valeant Pharmaceuticals International (VRX) has been rated by 12 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $90 and the lowest price target forecast is $11. The average forecast of all the analysts is $39.75 and the expected standard deviation is $19.53. The stock has recorded a 20-day Moving Average of 6.65% and the 50-Day Moving Average is 11.26%.

Valeant Pharmaceuticals International (NYSE:VRX): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $23.96 and $22.72 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $24.25. The buying momentum continued till the end and the stock did not give up its gains. It closed at $23.49, notching a gain of 1.86% for the day. The total traded volume was 43,033,597 . The stock had closed at $23.06 on the previous day.

Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *